# Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

> **NCT05272826** · PHASE2 · RECRUITING · sponsor: **Canadian Myeloma Research Group** · enrollment: 75 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Iberdomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT05272826
- **Lead sponsor:** Canadian Myeloma Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2028-03
- **Final completion:** 2031-03
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05272826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05272826, "Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05272826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*